Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results
Longboard Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharma to Present at Two Upcoming Investor Conferences in February
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock
Longboard Pharma Announces Pricing of Upsized Public Offering of Common Stock
Longboard’s shares triple as epilepsy med halves seizure rates